ELEV Elevation Oncology
- 3.620
- -0.025-0.69%
- 3.620
- 0.0000.00%
Elevation Oncology News
Elevation Oncology Analyst Ratings
Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
Elevation Oncology (ELEV) Receives a Buy From TD Cowen
Wedbush Maintains Outperform on Elevation Oncology, Raises Price Target to $8
Elevation Oncology Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)
JMP Securities Initiates Coverage On Elevation Oncology With Market Outperform Rating, Announces Price Target of $7
Elevation Oncology Analyst Ratings
Optimistic Buy Rating for Elevation Oncology on EO-3021's Promising Clinical Advancements and Differentiation
HC Wainwright & Co. Maintains Buy on Elevation Oncology, Raises Price Target to $6
Elevation Oncology Analyst Ratings
Elevation Oncology Analyst Ratings
Elevation Oncology's Robust Financial Position and Promising Clinical Trial Data Drive Buy Rating
Buy Rating on Elevation Oncology's Stock Supported by EO-3021 Clinical Program Progress and Potential Cash Boost
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), Sotera Health (SHC) and Elevation Oncology (ELEV)
Elevation Oncology Analyst Ratings
Wedbush Trims Elevation Oncology's Price Target to $5 From $6, Keeps Outperform Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevation Oncology (ELEV), Novartis AG (Six Swiss: CH:NOVN) and VBI Vaccines (VBIV)
Wedbush Lifts Elevation Oncology's Price Target to $6 From $4 on 'Impressive' Data, Keeps Outperform Rating
Analysis
Price Target
No Data
